The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy

N. Mehrotra, M. Gupta, A. Kovar, Bernd Meibohm

Research output: Contribution to journalReview article

79 Citations (Scopus)

Abstract

Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE)5 inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic (PK) properties and their PDE5 inhibitory activity profile. This review outlines the basic concepts of pharmacokinetics and pharmacokinetic pharmacodynamic (PK/PD) relationships and their relevance to dose selection and applied pharmacotherapy. It is followed by a detailed comparative discussion on the pharmacokinetics and exposure-response relationship of the currently available PDE5 inhibitors, including known drug-drug interactions and dosage adjustments in special populations. The review is aimed at providing a critical assessment of the pharmacokinetics of PDE5 inhibitors, which may assist clinicians in tailoring drug and/or treatment regimens to the unique needs of each individual patient with erectile dysfunction.

Original languageEnglish (US)
Pages (from-to)253-264
Number of pages12
JournalInternational Journal of Impotence Research
Volume19
Issue number3
DOIs
StatePublished - May 1 2007

Fingerprint

Phosphodiesterase 5 Inhibitors
Pharmacokinetics
Therapeutics
Social Adjustment
Clinical Pharmacology
Erectile Dysfunction
Drug Interactions
Pharmaceutical Preparations
Drug Therapy
Population

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. / Mehrotra, N.; Gupta, M.; Kovar, A.; Meibohm, Bernd.

In: International Journal of Impotence Research, Vol. 19, No. 3, 01.05.2007, p. 253-264.

Research output: Contribution to journalReview article

@article{8f2ddecf63564c93987d2c488bdbb8b3,
title = "The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy",
abstract = "Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE)5 inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic (PK) properties and their PDE5 inhibitory activity profile. This review outlines the basic concepts of pharmacokinetics and pharmacokinetic pharmacodynamic (PK/PD) relationships and their relevance to dose selection and applied pharmacotherapy. It is followed by a detailed comparative discussion on the pharmacokinetics and exposure-response relationship of the currently available PDE5 inhibitors, including known drug-drug interactions and dosage adjustments in special populations. The review is aimed at providing a critical assessment of the pharmacokinetics of PDE5 inhibitors, which may assist clinicians in tailoring drug and/or treatment regimens to the unique needs of each individual patient with erectile dysfunction.",
author = "N. Mehrotra and M. Gupta and A. Kovar and Bernd Meibohm",
year = "2007",
month = "5",
day = "1",
doi = "10.1038/sj.ijir.3901522",
language = "English (US)",
volume = "19",
pages = "253--264",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy

AU - Mehrotra, N.

AU - Gupta, M.

AU - Kovar, A.

AU - Meibohm, Bernd

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE)5 inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic (PK) properties and their PDE5 inhibitory activity profile. This review outlines the basic concepts of pharmacokinetics and pharmacokinetic pharmacodynamic (PK/PD) relationships and their relevance to dose selection and applied pharmacotherapy. It is followed by a detailed comparative discussion on the pharmacokinetics and exposure-response relationship of the currently available PDE5 inhibitors, including known drug-drug interactions and dosage adjustments in special populations. The review is aimed at providing a critical assessment of the pharmacokinetics of PDE5 inhibitors, which may assist clinicians in tailoring drug and/or treatment regimens to the unique needs of each individual patient with erectile dysfunction.

AB - Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE)5 inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic (PK) properties and their PDE5 inhibitory activity profile. This review outlines the basic concepts of pharmacokinetics and pharmacokinetic pharmacodynamic (PK/PD) relationships and their relevance to dose selection and applied pharmacotherapy. It is followed by a detailed comparative discussion on the pharmacokinetics and exposure-response relationship of the currently available PDE5 inhibitors, including known drug-drug interactions and dosage adjustments in special populations. The review is aimed at providing a critical assessment of the pharmacokinetics of PDE5 inhibitors, which may assist clinicians in tailoring drug and/or treatment regimens to the unique needs of each individual patient with erectile dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=34247876061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247876061&partnerID=8YFLogxK

U2 - 10.1038/sj.ijir.3901522

DO - 10.1038/sj.ijir.3901522

M3 - Review article

C2 - 16988721

AN - SCOPUS:34247876061

VL - 19

SP - 253

EP - 264

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 3

ER -